Subtle Medical has raised $33 million in growth capital, anchored by a Series C financing, that brings the company's total capital raised to $86 million.
The new capital will be used to accelerate product development, expand commercial adoption globally, and scale the company's vendor-neutral AI imaging platform across MRI, PET, and CT workflows, according to an announcement.
Morgan Stanley Expansion Capital led the financing with Korea-based Shinhan Venture Investment and existing investors, Fusion Fund, EnvisionX, BRV, and Samsung Ventures participating.
Coinciding with the funding, the company named Ohad Arazi as CEO to accelerate global enterprise expansion. Previously, Arazi served as president and CEO of Clarius Mobile Health.
Subtle Medical's co-founder and former CEO Enhao Gong, PhD, has transitioned to the role of chief science officer. Gong will lead the company's scientific roadmap and continue supporting operations and partnerships in China, the company noted.
